G

GSK

Develops medicines, vaccines, and consumer health

Global Marketing Manager - Oncology

Full-Time
No salary listed
Senior
Bachelor's, Master's, MBA, PhD
Upper Providence Township, PA, USA+2 moreMore locations: Philadelphia, PA, USA | Durham, NC, USA
HybridRegular on-site work is required, with remote time for focused work.
Growth & MarketingProduct Marketing

About the job

Requirements
  • A bachelor's degree or equivalent practical experience is required.
  • At least 5 years of pharmaceutical, biotech, or healthcare marketing experience is required.
  • Experience developing and executing omnichannel healthcare professional and/or patient campaigns is required.
  • Ability to lead cross-functional, matrixed teams and influence without direct authority is required.
  • Strong analytical skills and experience using insights and data to set key performance indicators and measure campaign performance are required.
  • Willingness and ability to travel domestically and internationally up to 25% as business needs require.
Responsibilities
  • Provide input to the strategic and operational business plan, and develop and deliver global marketing campaigns based on key customer/consumer and competitive insights, ensuring engagement with co-create countries.
  • Lead the identification, development, and execution of key healthcare professional stakeholder initiatives for congresses in partnership with global, regional, and local cross-functional team members.
  • Drive and support best-in-class launch readiness across all local operating companies.
  • Partner with key local operating companies to ensure global-to-local utilization rates meet required standards, and analyze and track campaigns for timely course correction.
  • Understand how to leverage promotional channels to support desired business outcomes and local operating company decision-making.
  • Manage partner agency relationships, workflows, and related expense budgets.
  • Manage agency-of-record interactions for strategic and promotional initiatives that support brand strategy.
  • Manage budgets, maintain a clear overview of spend allocation, and maximize resources.
  • Coordinate briefs for marketing tactics and oversee end-to-end project management.
  • Partner with cross-functional teams and external partners to define key performance indicators and analyze ongoing performance of key commercial programs.
  • Facilitate best-practice sharing and implement insights and course-correction plans across markets based on campaign insights and metrics.
  • Assess risks to performance and trust pillars and ensure impactful mitigation where required.
Desired Qualifications
  • An advanced degree such as an MBA, Master of Public Health, PhD, or related postgraduate qualification.
  • Experience in oncology or another specialty therapeutic area.
  • Experience in product launch planning and lifecycle management.
  • Familiarity with customer relationship management systems, campaign measurement platforms, and digital analytics tools.
  • Experience managing agencies, speaker programs, and global/local alignment processes.
  • Prior work in a global matrix environment and experience adapting strategy across regions.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Associated Press
Oct 21st, 2026
FDA approves GSK's Hibsago, offering 19% functional cure rate for chronic hepatitis B

The US Food and Drug Administration (FDA) has approved GSK's Hibsago (bepirovirsen) for chronic hepatitis B in adults without cirrhosis. It is used alongside nucleos(t)ide analogue therapy in patients with suppressed viral DNA and surface antigen levels of 3,000 IU/ml or below. GSK says it is the first treatment of its kind to offer a potential functional cure after six months. Patients can self-administer after the first dose. In B-Well phase III trials, 19% of patients reached functional cure (233 of 1,220), against none of 614 on placebo. Standard care typically achieves less than 1% after a year. The most common adverse events were injection site redness, local pain, and a temporary rise in a liver enzyme. The label carries a boxed warning for liver flares and low platelet counts. GSK licensed the drug from Ionis. It is also approved in Japan.

Associated Press
Oct 19th, 2026
FDA approves Jemperli as first immunotherapy for MSI-H/dMMR rectal cancer, with 68% response

The US Food and Drug Administration (FDA) has approved GSK's Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). AnaptysBio, which manages the financial collaboration for the drug, announced the approval on October 19, 2026. The decision rests on the AZUR-1 trial. Among evaluable patients, 68% (98 of 144) had a sustained clinical complete response at 12 months, according to investigator assessment. No recurrences have been reported among responders after a median follow-up of more than two years. Jemperli alone could help eligible patients avoid chemotherapy, radiation, and surgery. Serious adverse reactions occurred in 20% of patients. GSK will present full interim data at the ESMO Congress in Madrid on October 25, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

The Reporter
Oct 15th, 2026
Officials announce $2.9 billion from Merck to expand vaccine and medicine manufacturing in Montco.

Officials announce $2.9 billion from Merck to expand vaccine and medicine manufacturing in Montco. Company is currently in tax dispute with local district, township. PUBLISHED: October 15, 2026 at 1:32 PM EDT UPDATED: October 15, 2026 at 1:38 PM EDT UPPER GWYNEDD - Governor Josh Shapiro and Pennsylvania Department of Community and Economic Development Secretary Rick Siger announced on Wednesday that the state has secured a $2.9 billion investment from Merck global biopharmaceutical company to expand its operations in Montgomery County by the end of 2030. Pennsylvania is investing $5 million in the company's expansion, which will support the manufacturing of lifesaving products and medicine discovery, according to a statement from Shapiro and Siger. As part of the $2.9 billion commitment, Merck is investing $550 million in ADVANCE, a state-of-the-art robotics and AI-enabled drug research and development facility at its West Point Campus, and the nearby Springhouse Innovation Park R&D facility, which will help the company produce life-saving medicines. "My administration has made life sciences a key part of our economic development strategy here in Pennsylvania, and Merck's major investment in Montgomery County is another major win for the commonwealth," said Shapiro in a statement from his office. "We are proud to partner with Merck as they expand their operations in Montgomery County, advance cutting-edge research and manufacturing, and create new opportunities for thousands of Pennsylvanians. The life sciences industry is booming in Pennsylvania and I am committed to winning more investments like this and making sure our commonwealth remains a national leader in innovation, medicine, and manufacturing." A week earlier, also in Montgomery County, Shapiro and Siger announced that pharma giant GSK will invest more than $800 million to expand its facilities in King of Prussia, establishing a biopharmaceutical innovation and manufacturing hub, integrating commercial production, research and development and advanced digital capabilities in a single site. Funding from RCAP. Merck received a funding proposal from DCED for a $5 million Redevelopment Assistance Capital Program grant for the first West Point projects. Shapiro and Siger were at Merck's West Point campus Wednesday to help cut the ribbon on the ADVANCE facility. West Point plays a critical role in global public health, manufacturing over 200 million doses of vaccines a year. "Merck's continued investment in Montgomery County is a testament to Pennsylvania's strength as a global hub for life sciences, innovation, and advanced manufacturing," said Siger. "The commonwealth's $5 million RACP investment is helping support projects that will strengthen Merck's operations, advance the development and manufacturing of critical medicines and vaccines, and reinforce our competitive edge in an industry that is extremely important in Pennsylvania." In July, Upper Gwynedd Township officials announced that Merck was developing plans for a new manufacturing facility on their West Point campus, the most recent of several approved and built since the start of the 2020s, including expanding the existing "Building 45" for labs and office space in October 2020, a new "Building 50" of roughly 101,000 square feet of manufacturing space in February 2021, a new "Building 32" for freezer space approved in May 2021, expansion of the proposed "Building 50" in August 2021, and a new "Building 63A" production facility approved in November 2021. Merck also secured approvals in 2024 for a new "Building 41" toward the center of the company's 320-acre complex and in 2025 secured approvals from the township to swap preservation of wetlands on the site for another parcel elsewhere in the region. In September township officials approved the latest plans, for a vaccine manufacturing facility of roughly 75,000 square feet. The company, township, and North Penn School District have also been in a dispute over the firm's tax bill since early May, when Upper Gwynedd's staff asked that township's commissioners to approve a contract for new assessments of two properties township's comprising the West Point campus. In June the district hired a special counsel to handle the matter, and in September the school board created a new fund to keep Merck tax payments separate, saying the company was 'paying in protest' during the dispute. Joining Shapiro and Riger on Wedneday, Rob Davis, chairman and CEO of Merck, said, "The ADVANCE facility represents the future of clinical development at Merck and underscores our continued commitment to addressing the needs of the patients we serve." "This builds on our longstanding presence in Pennsylvania where we're proud to invest in the people, communities and scientific capabilities that will help drive the next generation of medicines," he said.

Seeking Alpha
Oct 14th, 2026
GSK plans more than 1,200 job cuts in Belgium.

GSK plans more than 1,200 job cuts in Belgium. GSK (GSK) plans to cut up to 1,217 jobs in Belgium as part of a proposed restructuring affecting research and development, production, and international support services, according to multiple Belgian media reports. The plan covers 482 white-collar employees and 735 management positions, according to union ABVV Chemie. Production-floor worker positions are reportedly excluded from the proposed reorganization. GSK (GSK) outlined the restructuring at a special works council meeting on Wednesday, October 14. The proposed changes affect GSK Biologicals, the group's vaccine business, according to a local report. GSK (GSK) employs about 8,500 people across its Belgian sites in Wavre, Rixensart and Gembloux. The proposed cuts follow a reduction of more than 400 jobs in Belgium during 2025, mainly through temporary-contract non-renewals and voluntary departure. Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market.